Mesenchymal Stromal Cells Equipped by IFNα Empower T Cells with Potent Anti-tumor Immunity
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA767037 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR16100804_1.fastq.gz | Fastqsanger.gz | |||
| SRR16100804_2.fastq.gz | Fastqsanger.gz | |||
| SRR16100805_1.fastq.gz | Fastqsanger.gz | |||
| SRR16100805_2.fastq.gz | Fastqsanger.gz | |||
| SRR16100806_1.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 8 |
Similar Datasets
Project description:Cancer treatments have been revolutionized by the emergence of immune checkpoint blockade therapies. However, only a minority of patients with various tumor types have benefited from such treatments. New strategies focusing on the immune contexture of the tumor tissue microenvironment hold great promises. Here, we created IFNα-overexpressing mesenchymal stromal cells (IFNα-MSCs). Upon direct injection into tumors, we found that these cells are powerful in eliminating several types of tumors. Interestingly, the intra-tumoral injection of IFNα-MSCs could also induce specific anti-tumor effects on distant tumors. These IFNα-MSCs promoted tumor cells to produce CXCL10, which in turn potentiates the infiltration of CD8+ T cells in the tumor site. Furthermore, IFNα-MSCs enhanced the expression of granzyme B (GZMB) in CD8+ T cells and invigorated their cytotoxicity in a Stat3-dependent manner. Genetic ablation of Stat3 in CD8+ T cells impaired the effect of IFNα-MSCs on GZMB expression. Importantly, combination of IFNα-MSCs and PD-L1 blockade induced an even stronger anti-tumor immunity. Therefore, IFNα-MSCs represent a novel tumor immunotherapy strategy, especially when combined with PD-L1 blockade.
2021-10-31 | GSE184918 | GEO
Project description:Cancer treatments have been revolutionized by the emergence of immune checkpoint blockade therapies. However, only a minority of patients with various tumor types have benefited from such treatments. New strategies focusing on the immune contexture of the tumor tissue microenvironment hold great promises. Here, we created IFNα-overexpressing mesenchymal stromal cells (IFNα-MSCs). Upon direct injection into tumors, we found that these cells are powerful in eliminating several types of tumors. Interestingly, the intra-tumoral injection of IFNα-MSCs could also induce specific anti-tumor effects on distant tumors. These IFNα-MSCs promoted tumor cells to produce CXCL10, which in turn potentiates the infiltration of CD8+ T cells in the tumor site. Furthermore, IFNα-MSCs enhanced the expression of granzyme B (GZMB) in CD8+ T cells and invigorated their cytotoxicity in a Stat3-dependent manner. Genetic ablation of Stat3 in CD8+ T cells impaired the effect of IFNα-MSCs on GZMB expression. Importantly, the combination of IFNα-MSCs and PD-L1 blockade induced an even stronger anti-tumor immunity. Therefore, IFNα-MSCs represent a novel tumor immunotherapy strategy, especially when combined with PD-L1 blockade.
| S-EPMC8956510 | biostudies-literature
Project description:Engineering A Potent Cancer Vaccine Using Immunoproteasome-Expressing Mesenchymal Stromal Cells
| PRJNA758967 | ENA
Project description:Interferon-α (IFNα) plays a key role in innate immunity by inducing interferon-stimulated genes (ISGs). Beyond protein-coding ISGs, non-coding RNAs such as microRNAs are also modulated by IFNα. Here, we profiled differentially expressed microRNAs in HepG2 cells following IFNα stimulation, providing new insights into interferon signaling and antiviral regulation.
2025-09-09 | GSE306696 | GEO
Project description:MicroRNAs induced by IFNα in HepG2 cells
| PRJNA1311834 | ENA
Project description:This SuperSeries is composed of the following subset Series: GSE17299: Direct effects of IFNα on human CD8 T cells_without any other concomitant signals GSE17301: The effect of IFNα on human CD8 T cells_with other concomitant signals Refer to individual Series
2010-07-23 | E-GEOD-17302 | biostudies-arrayexpress
Project description:The cause of systemic lupus erythematosus (SLE) is unknown. Interferonα (IFNα) has been suggested as a causative agent of SLE, however, it is not proven, and to what extent and how IFNα contributes to the disease is unknown. We here directly studied the contribution of IFNα to SLE by generating inducible IFNα transgenic mice which showed that conditional up-regulation of IFNα induced a typical manifestation of SLE including serum immune complex (IC), autoantibody against double stranded DNA (anti-dsDNA Ab) and the organ manifestations classical to SLE such as IC-deposited glomerulonephritis, classical splenic onion-skin lesion, and alopecia, epidermal liquefaction, positive lupus-band test of the skin. In the spleen of mice, activated effector CD4 T cells, interferonγ-producing CD8 T cells, B220+CD86+ cells and CD11c+CD86+ cells were increased, and the T cells produced increased amounts of IL-4, IL-6, IL-17 and IFNγ and decreased IL-2. In particular, activated CD3+CD4-CD8- double-negative T (DNT) cells positive for TCRαβ, B220, CD1d-teteramer, PD-1 and Helios, which produced increased amounts of IFNγ, IL-4, IL-17 and TNFα, were significantly expanded. They infiltrated into kidney and induced de novo glomerulonephritis and alopecia when transferred into naïve recipients. Thus, conditional up-regulation of IFNα is sufficient to induce SLE, and the DNT cells as expanded by IFNα are directly responsible for the organ manifestations such as lupus skin disease or nephritis.
2018-12-10 | GSE123549 | GEO
Project description:To investigate differentially expressed genes (DEGs) upon challenge with infectious salmon anemia virus (ISAV) or infectious pancreatic necrosis virus (IPNV) after IFNα treatment, in comparison to untreated cells. To examine the differentially expressed genes (DEGs) in knock-out (KO) cells with specific IFN receptors knockout, following IFNα treatment and infection with ISAV or IPNV. The expression profiles of these KO cells were compared with non-KO cells also treated with IFNα and infected with ISAV or IPNV.
2023-12-01 | E-MTAB-13068 | biostudies-arrayexpress
Project description:Apolipoprotein A-I mimetic peptides are amphipathic alpha-helix peptides that display similar functions to apolipoprotein A-I. Preclinical and clinical studies have demonstrated the safety and efficacy of apolipoprotein A-I mimetic peptides in multiple indications associated with inflammatory processes. In this study, we evaluated the effect of the long-term expression of L37pA in the liver by an adeno-associated virus (AAV-L37pA) on the expression of an adeno-associated virus encoding interferon-alpha (AAV-IFNα). Long-term IFNα expression in the liver leads to lethal hematological toxicity one month after AAV administration. Concomitant administration of AAV-L37pA prevented the lethal toxicity since the IFNα expression was reduced one month after AAV administration by decreasing the expression of IFNα. To identify the mechanism of action of L37pA, a genomic and proteomic analysis was performed fifteen days after AAV administration when a similar level of IFNα and interferon-stimulated genes were observed in mice treated with AAV-IFNα alone and in mice treated with AAV-IFNα and AAV-L37pA. The coexpression of the apolipoprotein A-I mimetic peptide L37pA with IFNα modulated the gene expression program of IFNα, inducing a significant reduction in inflammatory pathways affecting pathogen-associated molecular patterns receptor, dendritic cells, NK cells and Th1 immune response. The proteomic analysis confirmed the impact of the L37pA activity on several inflammatory pathways and indicated an activation of LXR/RXR and PPPARα/γ nuclear receptors. Thus, long-term expression of L37pA induces an anti-inflammatory effect in the liver that allows silencing of IFNα expression mediated by an adeno-associated virus.
2021-09-09 | PXD023281 | Pride
Project description:Hepatic metastases are a distinctive negative prognostic hallmark of colorectal cancer (CRC), thus there is an urgent need to develop new strategies aimed at reducing the risk of liver CRC colonization. Herein we demonstrate that adjuvant steady interferon-alpha (IFNα) administration, intravascularly control invading CRC cells through its direct action on liver sinusoidal endothelial cells (LSECs). Mechanistically, steady IFNα promotes the development of a vascular anti-metastatic niche, characterized by LSEC defenestration, extracellular matrix remodeling and glycocalyx deposition that reinforce the liver vascular barrier impairing CRC transendothelial migration. Furthermore, IFNα promotes LSEC-mediated innate and adaptive immunity, including antigen processing and presentation, that along with the early intravascular reduction of tumor burden, promote anti-tumor CD8+ T cell cross-priming and the generation of a protective long-term anti-tumor-memory response.
2022-10-19 | GSE186203 | GEO